← Back to Search

Simplified Language for Autism (PALS Trial)

N/A
Recruiting
Research Sponsored by Michigan State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up single assessment; total duration less than 10 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial will examine how single-word and telegraphic simplification affect language processing and word learning in young children with ASD.

Who is the study for?
This trial is for young children aged 1-4 who have been diagnosed with autism spectrum disorder or are suspected to have it, confirmed through ADOS-2. They must primarily speak English. Children with genetic conditions like Down syndrome, brain injuries, cerebral palsy, or uncorrected vision/hearing issues cannot participate.
What is being tested?
The study is testing how simplifying language in different ways affects the ability of young autistic children to process and learn new words. It compares full sentences to single-word and short phrases (telegraphic speech) to see which supports better understanding and learning.
What are the potential side effects?
Since this trial involves linguistic intervention rather than medication, there aren't typical side effects as seen in drug trials. However, variations in language exposure could potentially influence a child's natural language development patterns.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~single assessment; total duration less than 10 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and single assessment; total duration less than 10 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Gaze location on Looking-While-Listening (LWL) tasks
Secondary study objectives
Gaze location in Teaching Phase of Study 2b (Fast Mapping)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Utterance TypeExperimental Treatment1 Intervention
This study uses a within-participant experimental manipulation. All participants will be exposed to all utterance types (across trials).

Find a Location

Who is running the clinical trial?

Michigan State UniversityLead Sponsor
198 Previous Clinical Trials
685,136 Total Patients Enrolled
8 Trials studying Autism Spectrum Disorder
1,765 Patients Enrolled for Autism Spectrum Disorder
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
353 Previous Clinical Trials
181,373 Total Patients Enrolled
12 Trials studying Autism Spectrum Disorder
1,056 Patients Enrolled for Autism Spectrum Disorder

Media Library

Linguistic simplification Clinical Trial Eligibility Overview. Trial Name: NCT05707923 — N/A
Autism Spectrum Disorder Research Study Groups: Utterance Type
Autism Spectrum Disorder Clinical Trial 2023: Linguistic simplification Highlights & Side Effects. Trial Name: NCT05707923 — N/A
Linguistic simplification 2023 Treatment Timeline for Medical Study. Trial Name: NCT05707923 — N/A
~66 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top